Clinical trials recruiting for Non Small Cell Lung Carcinoma
10
Recruiting trials
39
US states with sites
32
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 5 |
| Massachusetts | 4 |
| New York | 4 |
| Ohio | 4 |
| Texas | 4 |
| Virginia | 4 |
| Colorado | 3 |
| Florida | 3 |
| Pennsylvania | 3 |
| Washington | 3 |
| Arizona | 2 |
| Delaware | 2 |
Top cities
Cleveland, Ohio 4Boston, Massachusetts 3Houston, Texas 3La Jolla, California 3Aurora, Colorado 2Austin, Texas 2Dallas, Texas 2Denver, Colorado 2Detroit, Michigan 2Durham, North Carolina 2
Self-screener
Recruiting trials
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
- Retifanlimab and Ruxolitinib In Solid Malignancies
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Related conditions
Trials recruiting for Non Small Cell Lung Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Triple-negative breast cancer 138Renal cell carcinoma 28Non-small cell lung cancer 507Non Small Cell Lung Cancer Metastatic 16Metastatic Solid Tumor 22Breast cancer 2239TNBC 5Small Cell Lung Carcinoma 20Small Cell Lung Cancer ( SCLC ) 29
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Non Small Cell Lung Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.